Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,089 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study.
Ou X, Wu J, Wu J, Fu Y, Zeng Z, Li S, Li Y, Liu D, Li H, Li B, Zhou J, Zhuang S, Cheng S, Zhang Z, Wang K, Qu S, Yan M. Ou X, et al. Among authors: zeng z. Cancer Res Treat. 2024 Oct;56(4):1207-1218. doi: 10.4143/crt.2023.1165. Epub 2024 Apr 30. Cancer Res Treat. 2024. PMID: 38697847 Free PMC article.
Should associating liver partition and portal vein ligation for staged hepatectomy be applied to hepatitis B virus-related hepatocellular carcinoma patients with cirrhosis? A multi-center study.
Lv JH, Chen WZ, Li YN, Wang JX, Fu YK, Zeng ZX, Wu JY, Wang SJ, Huang XX, Huang LM, Huang RF, Wei YG, Yan ML. Lv JH, et al. HPB (Oxford). 2022 Dec;24(12):2175-2184. doi: 10.1016/j.hpb.2022.10.001. Epub 2022 Oct 5. HPB (Oxford). 2022. PMID: 36280426 Free article.
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study.
Wu JY, Zhang ZB, Zhou JY, Ke JP, Bai YN, Chen YF, Wu JY, Zhou SQ, Wang SJ, Zeng ZX, Li YN, Qiu FN, Li B, Yan ML. Wu JY, et al. Liver Cancer. 2022 Nov 30;12(3):229-237. doi: 10.1159/000528356. eCollection 2023 Aug. Liver Cancer. 2022. PMID: 37767067 Free PMC article.
Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy.
Luo MC, Wu JY, Wu JY, Lin ZT, Li YN, Zeng ZX, Wei SM, Yan ML. Luo MC, et al. J Hepatocell Carcinoma. 2023 Oct 12;10:1827-1837. doi: 10.2147/JHC.S425674. eCollection 2023. J Hepatocell Carcinoma. 2023. PMID: 37850079 Free PMC article.
Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics.
Wu J, Wu J, Li S, Luo M, Zeng Z, Li Y, Fu Y, Li H, Liu D, Ou X, Lin Z, Wei S, Yan M. Wu J, et al. Among authors: zeng z. Biosci Trends. 2024 Mar 19;18(1):42-48. doi: 10.5582/bst.2023.01326. Epub 2024 Feb 8. Biosci Trends. 2024. PMID: 38325823 Free article. Review.
9,089 results